Pacira BioSciences, Inc. (PCRX) AI Stock Analysis

Pacira BioSciences, Inc., based in Tampa, Florida, develops and commercializes non-opioid pain management and regenerative health treatments for healthcare providers and patients across the United States. Founded in 2006 as Pacira Pharmaceuticals and rebranded in April 2019, the company focuses on biotherapeutic alternatives to opioids. Its product portfolio includes EXPAREL, a bupivacaine liposome injectable suspension providing sustained postsurgical pain relief, and ZILRETTA, an extended-release injectable suspension for osteoarthritis knee pain. Pacira also markets the iovera system, a handheld cryoanalgesia device for nerve cold therapy, and utilizes proprietary multivesicular liposome technology to encapsulate drugs and sustain therapeutic delivery.

Pacira achieved a 5-year revenue compound annual growth rate of 11.1% from FY2020 to FY2025. Annual revenue expanded from $541.5M in FY2021 to $666.8M in FY2022 and $675.0M in FY2023. In FY2024, revenue climbed to $701.0M, but operating margin dropped to -10.5% resulting in a net loss of -$99.6M. For FY2025, revenue increased 3.6% to $726.4M with gross margin reaching 79.4%, operating margin recovering to 4.6%, and net income totaling $7.0M. In the latest quarter ended June 30, 2026, revenue rose 6.2% year-over-year, while quarterly earnings declined 30.0%. Trailing twelve month earnings per share stood at $0.35 on operating cash flow of $152.0M reported in FY2025.

As of June 30, 2026, Pacira BioSciences held $251.0M in cash and short-term investments against total debt of $412.1M, yielding net debt of $161.1M. Total assets were $1.24B compared to shareholders' equity of $672.0M, with a debt-to-equity ratio of 0.61 and a current ratio of 5.04. In FY2025, the company generated free cash flow of $136.7M after funding capital expenditures of $15.3M. Capital allocation in FY2025 included $148.3M directed toward share buybacks, contributing to a 5-year share count change of -9.6%.

At a closing price of $36.34 on October 16, 2026, Pacira trades at an enterprise value of $1.14B and a market capitalization of $1.45B. Its trailing price-to-earnings ratio is 103.8x, compared to 24.6x for the median of its US-listed Healthcare peers. Its forward price-to-earnings ratio is 6.2x, below the peer group median of 17.3x. Pacira's price-to-sales ratio sits at 1.9x versus the peer median of 4.1x, and its EV-to-EBITDA ratio is 9.8x versus 12.0x for peers. Over the past year, the stock returned 59.6% compared to 16.8% for the S&P 500 (SPY).

Consensus coverage across 9 analysts includes 1 Strong Buy, 8 Hold ratings, and zero Sell or Strong Sell ratings. The mean price target is $33.57, which represents a 7.6% discount to the last close of $36.34. For the fiscal year ending December 31, 2026, analysts estimate revenue of $754.3M and earnings per share of $2.90, reflecting estimated earnings growth of 9.3%. For FY2027, consensus estimates forecast revenue of $790.0M and earnings per share of $3.46. Over the last four quarters, the company topped earnings estimates in 3 quarters. The next earnings date is November 5, 2026.

This page is an AI-written research summary of Pacira BioSciences, Inc. (PCRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PCRX income statement, PCRX balance sheet, PCRX key metrics, PCRX analyst forecast, PCRX chart. See the PCRX stock overview for the latest quote and news.